128 related articles for article (PubMed ID: 7652492)
1. Tumour marker evaluation in patients with lung cancer.
Seregni E; Botti C; Bogni A; Bombardieri E
Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
[No Abstract] [Full Text] [Related]
2. Prognostic and diagnostic usefulness of serum markers in lung cancer.
Stahel RA; Martz G
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):893-4. PubMed ID: 2822425
[No Abstract] [Full Text] [Related]
3. Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.
Ledermann JA
Eur J Cancer; 1994; 30A(5):574-6. PubMed ID: 8080666
[No Abstract] [Full Text] [Related]
4. Serum tumour markers in lung cancer.
Hansen M
Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
[No Abstract] [Full Text] [Related]
5. Evaluation of "neuron-specific enolase" as a tumor marker for small cell carcinoma of the lung.
Güner G; Oktay G; Akkoçlu A; Karlikaya C
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):306S. PubMed ID: 8224452
[No Abstract] [Full Text] [Related]
6. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
[TBL] [Abstract][Full Text] [Related]
7. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.
Paone G; De Angelis G; Portalone L; Greco S; Giosué S; Taglienti A; Bisetti A; Ameglio F
Br J Cancer; 1997; 75(3):448-50. PubMed ID: 9020496
[TBL] [Abstract][Full Text] [Related]
8. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer.
O'Shea P; Cassidy M; Freaney R; McCarthy P; Fennelly J
Ir J Med Sci; 1995 Jan; 164(1):31-6. PubMed ID: 7890531
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
10. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1.
Paone G; De Angelis G; Munno R; Pallotta G; Bigioni D; Saltini C; Bisetti A; Ameglio F
Eur Respir J; 1995 Jul; 8(7):1136-40. PubMed ID: 7589398
[TBL] [Abstract][Full Text] [Related]
11. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
12. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
Hekmat K; Bruns C
Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
[No Abstract] [Full Text] [Related]
13. Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer.
Stieber P; Bodenmüller H; Banauch D; Hasholzner U; Dessauer A; Ofenloch-Hähnle B; Jaworek D; Fateh-Moghadam A
Clin Biochem; 1993 Aug; 26(4):301-4. PubMed ID: 7694815
[TBL] [Abstract][Full Text] [Related]
14. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
Muley T; Ebert W; Stieber P; Raith H; Holdenrieder S; Nagel D; Fürst H; Roth HJ; Luthe H; Blijenberg BG; Gurr E; Uhl W; von Pawel J; Drings P
Clin Chem Lab Med; 2003 Jan; 41(1):95-103. PubMed ID: 12636057
[TBL] [Abstract][Full Text] [Related]
15. Biomarker studies abound for early detection of lung cancer.
Brower V
J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
[No Abstract] [Full Text] [Related]
16. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Dowlati A; Bury T; Corhay JL; Weber T; Mendes P; Radermecker M
Cancer; 1996 May; 77(10):2039-43. PubMed ID: 8640667
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neurone-specific enolase and pro-gastrin releasing peptide in the prognostic evaluation of small cell lung cancer patients.
Satoh H; Kagohashi K; Kurishima K; Ishikawa H; Ohtsuka M
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):720. PubMed ID: 17100161
[No Abstract] [Full Text] [Related]
18. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
19. [Biological markers in lung cancer].
Nikliński J; Furman M
Pneumonol Alergol Pol; 1991; 59(5-6):253-9. PubMed ID: 1668877
[No Abstract] [Full Text] [Related]
20. Biomarkers in lung cancer.
Bearz A; Berretta M; Cappellani A; Lleshi A; Berto E; Fratino L; Tirelli U
Front Biosci (Elite Ed); 2010 Jun; 2(3):1099-104. PubMed ID: 20515780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
